JP6622222B2 - Ｔａｔ−ＮＲ２Ｂ９ｃの塩化物塩 - Google Patents

Ｔａｔ−ＮＲ２Ｂ９ｃの塩化物塩 Download PDF

Info

Publication number
JP6622222B2
JP6622222B2 JP2016569655A JP2016569655A JP6622222B2 JP 6622222 B2 JP6622222 B2 JP 6622222B2 JP 2016569655 A JP2016569655 A JP 2016569655A JP 2016569655 A JP2016569655 A JP 2016569655A JP 6622222 B2 JP6622222 B2 JP 6622222B2
Authority
JP
Japan
Prior art keywords
tat
nr2b9c
formulation
lyophilized
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016569655A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017517517A (ja
JP2017517517A5 (cg-RX-API-DMAC7.html
Inventor
ジョナサン デイヴィッド ガーマン，
ジョナサン デイヴィッド ガーマン，
Original Assignee
ノノ インコーポレイテッド
ノノ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノノ インコーポレイテッド, ノノ インコーポレイテッド filed Critical ノノ インコーポレイテッド
Publication of JP2017517517A publication Critical patent/JP2017517517A/ja
Publication of JP2017517517A5 publication Critical patent/JP2017517517A5/ja
Priority to JP2019210223A priority Critical patent/JP6961661B2/ja
Application granted granted Critical
Publication of JP6622222B2 publication Critical patent/JP6622222B2/ja
Priority to JP2021167771A priority patent/JP7338890B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
JP2016569655A 2014-05-28 2015-05-28 Ｔａｔ−ＮＲ２Ｂ９ｃの塩化物塩 Expired - Fee Related JP6622222B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2019210223A JP6961661B2 (ja) 2014-05-28 2019-11-21 Ｔａｔ−ＮＲ２Ｂ９ｃの塩化物塩
JP2021167771A JP7338890B2 (ja) 2014-05-28 2021-10-13 Ｔａｔ－ＮＲ２Ｂ９ｃの塩化物塩

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004142P 2014-05-28 2014-05-28
US62/004,142 2014-05-28
PCT/IB2015/053995 WO2015181756A1 (en) 2014-05-28 2015-05-28 Chloride salt of tat-nr2b9c

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019210223A Division JP6961661B2 (ja) 2014-05-28 2019-11-21 Ｔａｔ−ＮＲ２Ｂ９ｃの塩化物塩

Publications (3)

Publication Number Publication Date
JP2017517517A JP2017517517A (ja) 2017-06-29
JP2017517517A5 JP2017517517A5 (cg-RX-API-DMAC7.html) 2019-07-25
JP6622222B2 true JP6622222B2 (ja) 2019-12-18

Family

ID=54698210

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016569655A Expired - Fee Related JP6622222B2 (ja) 2014-05-28 2015-05-28 Ｔａｔ−ＮＲ２Ｂ９ｃの塩化物塩
JP2019210223A Expired - Fee Related JP6961661B2 (ja) 2014-05-28 2019-11-21 Ｔａｔ−ＮＲ２Ｂ９ｃの塩化物塩
JP2021167771A Active JP7338890B2 (ja) 2014-05-28 2021-10-13 Ｔａｔ－ＮＲ２Ｂ９ｃの塩化物塩
JP2023088154A Pending JP2023113751A (ja) 2014-05-28 2023-05-29 Ｔａｔ－ＮＲ２Ｂ９ｃの塩化物塩

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019210223A Expired - Fee Related JP6961661B2 (ja) 2014-05-28 2019-11-21 Ｔａｔ−ＮＲ２Ｂ９ｃの塩化物塩
JP2021167771A Active JP7338890B2 (ja) 2014-05-28 2021-10-13 Ｔａｔ－ＮＲ２Ｂ９ｃの塩化物塩
JP2023088154A Pending JP2023113751A (ja) 2014-05-28 2023-05-29 Ｔａｔ－ＮＲ２Ｂ９ｃの塩化物塩

Country Status (27)

Country Link
US (4) US10206973B2 (cg-RX-API-DMAC7.html)
EP (2) EP3149048B1 (cg-RX-API-DMAC7.html)
JP (4) JP6622222B2 (cg-RX-API-DMAC7.html)
KR (3) KR102605540B1 (cg-RX-API-DMAC7.html)
CN (2) CN106661126B (cg-RX-API-DMAC7.html)
AU (2) AU2015265487B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016027814A2 (cg-RX-API-DMAC7.html)
CA (1) CA2950395C (cg-RX-API-DMAC7.html)
CY (1) CY1122793T1 (cg-RX-API-DMAC7.html)
DK (1) DK3149048T3 (cg-RX-API-DMAC7.html)
ES (2) ES2784500T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20200462T1 (cg-RX-API-DMAC7.html)
HU (1) HUE049074T2 (cg-RX-API-DMAC7.html)
IL (1) IL249252B (cg-RX-API-DMAC7.html)
LT (1) LT3149048T (cg-RX-API-DMAC7.html)
ME (1) ME03790B (cg-RX-API-DMAC7.html)
MX (2) MX374958B (cg-RX-API-DMAC7.html)
PL (1) PL3149048T3 (cg-RX-API-DMAC7.html)
PT (1) PT3149048T (cg-RX-API-DMAC7.html)
RS (1) RS60625B1 (cg-RX-API-DMAC7.html)
RU (2) RU2707885C2 (cg-RX-API-DMAC7.html)
SG (2) SG10202001285XA (cg-RX-API-DMAC7.html)
SI (1) SI3149048T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202000307T1 (cg-RX-API-DMAC7.html)
UA (1) UA123820C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015181756A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201608843B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2172211E (pt) * 2008-10-01 2015-03-09 Immatics Biotechnologies Gmbh Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer
US10251935B2 (en) * 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
JP6707469B2 (ja) 2014-05-28 2020-06-10 ノノ インコーポレイテッド アセチル化スカベンジャーを含むＴａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤
LT3149048T (lt) 2014-05-28 2020-05-11 Nono Inc. Tat-nr2b9c chlorido druska
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
IL308735A (en) 2015-07-01 2024-01-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201620611D0 (en) * 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
BR112020000115A2 (pt) * 2017-07-05 2020-07-07 Biocells (Beijing) Biotech Co., Ltd. sais farmaceuticamente aceitáveis de polipeptídeos e uso dos mesmos
CN110627877A (zh) * 2019-09-25 2019-12-31 成都奥达生物科技有限公司 一种psd-95抑制剂
US20230055441A1 (en) * 2020-01-09 2023-02-23 Nono Inc. Plasmin-resistant peptides for treating stroke and related conditions
CN111560050A (zh) * 2020-05-25 2020-08-21 成都圣诺生物制药有限公司 一种Nerinetide的制备方法
BR112023013640A2 (pt) 2021-01-08 2023-12-05 Nono Inc Peptídeos resistentes à plasmina para índice terapêutico melhorado
CN113735938B (zh) * 2021-07-30 2024-11-08 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
PT2275119E (pt) * 1995-07-27 2013-11-21 Genentech Inc Formulação de proteína liofilizada isotónica estável
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
WO2007016366A2 (en) * 2005-07-29 2007-02-08 Yale University Defined culture conditions of human embryonic stem cells
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
EP1884521A1 (en) 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
EP2120987B1 (en) 2007-03-02 2014-01-15 NoNO Inc. Treating stroke and other diseases without inhibiting n-type calcium channels
MX2009012964A (es) * 2007-06-01 2010-01-14 Acologix Inc Formulacion de peptido estable a alta temperatura.
US8008253B2 (en) * 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
DK2320927T3 (en) * 2008-07-09 2015-09-14 Univ Copenhagen Modified peptides as potent inhibitors of the PSD-95 / NMDA receptor interaction
EP3808366A1 (en) * 2009-06-10 2021-04-21 NoNO Inc. Treatment regimes for treatment of neurological disease
CA2807946C (en) * 2010-08-12 2018-09-25 Nono Inc. Treatment of penetrative injury to the brain
EP2621945B1 (en) * 2010-09-28 2018-04-11 NoNO Inc. Nd2 peptides and methods of treating neurological disease
ES2544573T3 (es) * 2011-05-13 2015-09-01 Københavns Universitet (University Of Copenhagen) Inhibidores diméricos de afinidad elevada de PSD-95 y su uso para el tratamiento del daño cerebral isquémico y del dolor
CN102241745A (zh) * 2011-05-19 2011-11-16 南京医科大学 多肽类似物Tat-HA-NR2B9C及其制备方法和应用
HUE058238T2 (hu) * 2011-06-24 2022-07-28 Nono Inc Ischaemia kombinációs terápiája
US9241970B2 (en) * 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
JP6279483B2 (ja) 2011-12-13 2018-02-14 ノノ インコーポレイテッド くも膜下出血および虚血の治療法
GB201220474D0 (en) * 2012-11-14 2012-12-26 Sagetis Biotech Sl Polypeptides
HUE043820T2 (hu) 2012-11-28 2019-09-30 Nono Inc Liofilizált TAT-NR2B9c készítmény
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
JP6707469B2 (ja) * 2014-05-28 2020-06-10 ノノ インコーポレイテッド アセチル化スカベンジャーを含むＴａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤
LT3149048T (lt) * 2014-05-28 2020-05-11 Nono Inc. Tat-nr2b9c chlorido druska

Also Published As

Publication number Publication date
RS60625B1 (sr) 2020-09-30
AU2015265487A1 (en) 2017-01-12
JP2022023122A (ja) 2022-02-07
AU2020267304B2 (en) 2023-10-05
CN106661126B (zh) 2021-12-10
RU2707885C2 (ru) 2019-12-02
US11266714B2 (en) 2022-03-08
DK3149048T3 (en) 2020-04-14
PL3149048T3 (pl) 2020-06-29
ES2974228T3 (es) 2024-06-26
SG10202001285XA (en) 2020-04-29
UA123820C2 (uk) 2021-06-09
ZA201608843B (en) 2019-04-24
US20220175880A1 (en) 2022-06-09
AU2020267304C1 (en) 2024-03-14
EP3757134B1 (en) 2024-03-06
JP2023113751A (ja) 2023-08-16
US10758589B2 (en) 2020-09-01
MX374958B (es) 2025-03-06
ME03790B (me) 2021-04-20
PT3149048T (pt) 2020-04-21
SI3149048T1 (sl) 2020-08-31
US20190175689A1 (en) 2019-06-13
CA2950395C (en) 2023-03-21
KR20220082113A (ko) 2022-06-16
KR20210125109A (ko) 2021-10-15
US10206973B2 (en) 2019-02-19
SG11201609911YA (en) 2016-12-29
JP6961661B2 (ja) 2021-11-05
EP3149048A1 (en) 2017-04-05
HUE049074T2 (hu) 2020-08-28
US20200384071A1 (en) 2020-12-10
JP2017517517A (ja) 2017-06-29
EP3757134C0 (en) 2024-03-06
KR102311038B1 (ko) 2021-10-07
RU2016150678A (ru) 2018-07-02
MX2016015457A (es) 2017-06-30
SMT202000307T1 (it) 2020-07-08
CY1122793T1 (el) 2021-05-05
HRP20200462T1 (hr) 2020-10-16
IL249252A0 (en) 2017-02-28
CN114057895A (zh) 2022-02-18
EP3149048A4 (en) 2018-01-03
MX2020009633A (es) 2020-10-08
IL249252B (en) 2021-06-30
US11911438B2 (en) 2024-02-27
KR20170020820A (ko) 2017-02-24
CA2950395A1 (en) 2015-12-03
AU2015265487B2 (en) 2020-08-13
JP2020045352A (ja) 2020-03-26
LT3149048T (lt) 2020-05-11
JP7338890B2 (ja) 2023-09-05
CN106661126A (zh) 2017-05-10
EP3149048B1 (en) 2020-01-29
AU2020267304A1 (en) 2020-12-10
BR112016027814A2 (pt) 2017-10-24
RU2016150678A3 (cg-RX-API-DMAC7.html) 2018-12-25
KR102605540B1 (ko) 2023-11-22
ES2784500T3 (es) 2020-09-28
RU2019138024A (ru) 2019-12-05
WO2015181756A1 (en) 2015-12-03
EP3757134A1 (en) 2020-12-30
KR102407856B1 (ko) 2022-06-10
US20170119845A1 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
JP7338890B2 (ja) Ｔａｔ－ＮＲ２Ｂ９ｃの塩化物塩
JP6427104B2 (ja) Ｔａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤
US20220096383A1 (en) Lyophilized formulation of tat-nr2b9c with acetylation scavenger
HK40044216A (en) Chloride salt of tat-nr2b9c
HK1236205B (en) Chloride salt of tat-nr2b9c
HK1236205A1 (en) Chloride salt of tat-nr2b9c

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180508

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190319

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20190618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191009

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191023

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191121

R150 Certificate of patent or registration of utility model

Ref document number: 6622222

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees